Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Founder Says $61m Financing Will Allow ‘Developmental Lift Off’
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
